PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,